The Maraviroc Central Nervous System (CNS) Study

NCT ID: NCT00982878

Last Updated: 2019-11-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-09-30
• Study Completion Date: 2011-02-28

Brief Summary

The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.

Detailed Description

15 HIV-1 infected subjects currently receiving stable antiretroviral therapy will be recruited. At study entry, within 14 days of screening procedures, subjects will commence maraviroc dosed at 150 mg twice daily. For the rest of study period antiretroviral therapy will comprise:

• Truvada™ one tablet once daily at 0900
• Kaletra™ two tablets twice daily 0900 and 2100
• maraviroc 150 mg twice daily at 0900 and 2100

Subjects will attend for regular clinic visits during study treatment phase.

On day 15, subjects will attend the unit in the morning prior to usual dosing time. Blood with be drawn to assess plasma maraviroc concentration pre dose and pre lumbar puncture. A lumbar puncture will be performed under standard aseptic techniques to asses CSF maraviroc concentration and routine CSF parameters.

On completion of this study visit, subjects will cease maraviroc, continue on their usual antiretroviral regimen and attend for a follow up visit 10 days later.

Conditions

HIV Infections

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Maraviroc

Group Type: EXPERIMENTAL

Maraviroc

Intervention Type: DRUG

150mg twice daily

Interventions

Maraviroc

150mg twice daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• HIV-1 infected males or females
• signed informed consent
• plasma HIV RNA < 50 copies/mL at screening and on at least one other occasion over the last 3 months
• currently receiving a stable antiretroviral regimen comprising of:

• tenofovir 245 mg daily
• emtricitabine 200 mg daily
• a boosted protease inhibitor
• no previous protease inhibitor resistance documented on HIV-1 genotypic resistance testing
• Between 18 to 65 years of age, inclusive
• subjects in good health upon medical history, physical exam, and laboratory testing
• Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study including 30 days following last dose of study drug:

• barrier contraceptives (condom, diaphragm with spermicide)
• IUD PLUS a barrier contraceptive
• Female subjects of childbearing potential must have a negative pregnancy test.
• Male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study including 30 days following last dose of study drug.
• Have no serologic evidence of active HBV infection evidenced by negative hepatitis B surface antigen and no serologic evidence of hepatitis C virus infection by a HCV antibody or HCV PCR.
• Have screening laboratory results (haematology, chemistry, and urinalysis) that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the Investigator to have no clinical significance

Exclusion Criteria

• current alcohol abuse or drug dependence
• active opportunistic infection or significant co-morbidities including dementia
• current prohibited concomitant medication (as listed in section 4.1.4)
• Have a body mass index (BMI) > 32
• Contraindication to lumbar puncture examination. Such as:

• Existing neurological diseases
• Bleeding disorders

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

Imperial College London

OTHER

Sponsor Role: lead

Responsible Party

Alan Winston

Reader and Honorary HIV consultant

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Alan Winston

Role: PRINCIPAL_INVESTIGATOR

Imperial College London

Locations

Imperial College Healthcare NHS Trust

London, , United Kingdom

Countries

United Kingdom

References

Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. J Antimicrob Chemother. 2012 Jan;67(1):206-12. doi: 10.1093/jac/dkr427. Epub 2011 Oct 10.

Reference Type: RESULT

PMID: 21987241 (View on PubMed)

Other Identifiers

2008-008437-10

Identifier Type: -

Identifier Source: org_study_id